NASDAQ:SMFR Sema4 - SMFR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sema4 Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 +0.02 (+4.94%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.39▼$0.4350-Day Range$0.22▼$0.5352-Week Range$0.22▼$4.67Volume3.41 million shsAverage Volume2.37 million shsMarket Capitalization$160.26 millionP/E RatioN/ADividend YieldN/APrice Target$2.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sema4 MarketRank™ ForecastAnalyst RatingModerate Buy2.60 Rating ScoreUpside/Downside527.7% Upside$2.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$2.72 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.88) to ($0.53) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.98 out of 5 starsMedical Sector684th out of 1,053 stocksHealth Services Industry8th out of 12 stocks 3.3 Analyst's Opinion Consensus RatingSema4 has received a consensus rating of Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.67, Sema4 has a forecasted upside of 527.7% from its current price of $0.42.Amount of Analyst CoverageSema4 has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SMFR. Previous Next 0.0 Dividend Strength Dividend YieldSema4 does not currently pay a dividend.Dividend GrowthSema4 does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMFR. Previous Next 1.0 News and Social Media Coverage News SentimentSema4 has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Sema4 this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for SMFR on MarketBeat in the last 30 days. This is a decrease of -56% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sema4 insiders have sold 2,619.55% more of their company's stock than they have bought. Specifically, they have bought $100,000.00 in company stock and sold $2,719,554.00 in company stock.Percentage Held by Institutions56.01% of the stock of Sema4 is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Sema4 are expected to grow in the coming year, from ($0.88) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sema4 is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sema4 is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSema4 has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Sema4 (NASDAQ:SMFR) StockSema4 Holdings Corp., doing business as Sema4, operates as a health information company that enhances diagnosis, treatment, and prevention of disease through data. The company provides Centrellis, an AI-driven health intelligence platform that delivers comprehensive insights to biopharma to accelerate the drug discovery, development, and commercialization life-cycle, as well as analytics for actionable insights, pre-clinical and clinical trial support, and advanced sequencing services. It also offers Sema4 Signal that enables and advances precision oncology care, from prevention to treatment to remission; and testing for carrier screening, noninvasive prenatal testing, and newborn screening, as well as hereditary cancer testing. In addition, the company provides COVID-19 testing solutions. Sema4 Holdings Corp. was incorporated in 2020 and is headquartered in Stamford, Connecticut.Read More Receive SMFR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sema4 and its competitors with MarketBeat's FREE daily newsletter. Email Address SMFR Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comSema4 Holdings Corp. (NASDAQ:SMFR) Given Consensus Recommendation of "Moderate Buy" by AnalystsJanuary 9, 2023 | finance.yahoo.comSema4 Announces Name Change to GeneDx and Provides Preliminary 2022 Financial Results and 2023 GuidanceFebruary 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! December 30, 2022 | finance.yahoo.comSema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceDecember 5, 2022 | finance.yahoo.comNew Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICUNovember 28, 2022 | reuters.comSema4 Holdings CorpNovember 14, 2022 | finance.yahoo.comSema4 Reports Third Quarter 2022 Financial Results and New Strategic DirectionNovember 4, 2022 | finance.yahoo.comSema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022February 2, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! October 31, 2022 | finance.yahoo.comSema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained EpilepsiesOctober 27, 2022 | finance.yahoo.comSema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill NewbornsOctober 26, 2022 | finance.yahoo.comSema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panelsOctober 20, 2022 | finance.yahoo.comSMFR LAWSUIT ALERT: Levi & Korsinsky Notifies Sema4 Holdings, Corp. Investors of a Class Action Lawsuit and Upcoming DeadlineOctober 20, 2022 | benzinga.comROSEN, RESPECTED INVESTOR COUNSEL, Encourages Sema4 Holdings Corp. Investors With Losses to Secure Counse - BenzingaOctober 19, 2022 | benzinga.comCLASS ACTION UPDATE for NIO, SMFR and BCS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Be - BenzingaOctober 19, 2022 | benzinga.comDEADLINE ALERT for TSP, SMFR, TWTR, PLTR: Law Offices of Howard G. Smith Reminds Investors of Class Actio - BenzingaOctober 19, 2022 | benzinga.comSHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Sema4 Holdings Corp. with Losses - BenzingaOctober 18, 2022 | benzinga.comROSEN, Top Ranked Investor Counsel, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Im - BenzingaOctober 18, 2022 | benzinga.comSEMA4 HOLDINGS CORP. (NASDAQ: SMFR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Invest - BenzingaOctober 17, 2022 | benzinga.comROSEN, A LEADING LAW FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important D - BenzingaOctober 17, 2022 | globenewswire.comSMFR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Sema4 Holdings (SMFR) Investors with Significant Losses to Contact Firm's Attorneys, Securities Class Action Pending - GlobeNewswireOctober 16, 2022 | benzinga.comROSEN, A LEADING LAW FIRM, Encourages Sema4 Holdings Corp. Investors with Losses to Secure Counsel Before - BenzingaOctober 13, 2022 | benzinga.comSema4 Study Demonstrates The Utility Of Exome Sequencing For Diagnosing Autism Spectrum Disorders; Research From 19000 Patients With Autism Spectrum Disorders Found ~90% Had Prior Negative Tests - Sema4 Holdings (NASDAQ:SMFR) - BenzingaOctober 13, 2022 | finance.yahoo.comStudy Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum DisordersOctober 9, 2022 | globenewswire.comROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SMFR, SMFRW - GlobeNewswireOctober 9, 2022 | benzinga.comROSEN, A TOP RANKED FIRM, Encourages Sema4 Holdings Corp. Investors to Secure Counsel Before Important De - BenzingaOctober 8, 2022 | businesswire.comKirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Sema4 Holdings Corp. (SMFR; SMFRW) Investors and Encourages Investors to Contact the Firm Before November 7, 2022 - businesswire.comSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SMFR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sema4 and its competitors with MarketBeat's FREE daily newsletter. Email Address SMFR Company Calendar Last Earnings11/14/2022Today2/02/2023Next Earnings (Estimated)3/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Health services Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SMFR CUSIPN/A CIK1818331 Webcmlifesciencesspac.com Phone800-298-6470FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.67 High Stock Price Forecast$5.00 Low Stock Price Forecast$1.00 Forecasted Upside/Downside+527.7%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-245,390,000.00 Net Margins-121.31% Pretax Margin-142.57% Return on Equity-53.31% Return on Assets-36.04% Debt Debt-to-Equity Ratio0.02 Current Ratio1.89 Quick Ratio1.62 Sales & Book Value Annual Sales$212.20 million Price / Sales0.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book0.26Miscellaneous Outstanding Shares377,249,000Free FloatN/AMarket Cap$160.26 million OptionableOptionable Beta1.61 Key ExecutivesMr. Jason Ryan (Age 49)Exec. Chair of the Board Comp: $30kMr. Isaac RoConsultantMs. Katherine A. Stueland (Age 47)CEO & Director Mr. Kevin FeeleySr. VP of Operations & CFOMr. Robert Sebra Ph.D.VP of Technology Devel.Dr. Matthew Davis Ph.D.Chief Technology & Product OfficerDr. Gustavo Stolovitzky Ph.D.Chief Science OfficerMr. Murali ManiChief Compliance & Privacy OfficerMs. Karen White (Age 52)Chief People Officer Mr. Kareem M. Saad (Age 43)Chief Transformation Officer More ExecutivesKey CompetitorsPear TherapeuticsNASDAQ:PEARFuture Health ESGNASDAQ:FHLTP3 Health PartnersNASDAQ:PIIIThe Pennant GroupNASDAQ:PNTGChimerixNASDAQ:CMRXView All CompetitorsInsiders & InstitutionsTrellus Management Company LLCBought 657,100 shares on 1/27/2023Ownership: 0.292%Karen Ann WhiteSold 1,630 sharesTotal: $423.80 ($0.26/share)Bank of New York Mellon CorpBought 149,799 shares on 12/8/2022Ownership: 0.226%Kevin FeeleySold 8,465 sharesTotal: $3,386.00 ($0.40/share)Keith A MeisterSold 6,789,360 sharesTotal: $2.72 M ($0.40/share)View All Insider TransactionsView All Institutional Transactions SMFR Stock - Frequently Asked Questions Should I buy or sell Sema4 stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sema4 in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SMFR shares. View SMFR analyst ratings or view top-rated stocks. What is Sema4's stock price forecast for 2023? 5 equities research analysts have issued 12 month price objectives for Sema4's shares. Their SMFR share price forecasts range from $1.00 to $5.00. On average, they predict the company's stock price to reach $2.67 in the next year. This suggests a possible upside of 527.7% from the stock's current price. View analysts price targets for SMFR or view top-rated stocks among Wall Street analysts. How have SMFR shares performed in 2023? Sema4's stock was trading at $0.2638 on January 1st, 2023. Since then, SMFR stock has increased by 61.0% and is now trading at $0.4248. View the best growth stocks for 2023 here. When is Sema4's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023. View our SMFR earnings forecast. How were Sema4's earnings last quarter? Sema4 Holdings Corp. (NASDAQ:SMFR) released its quarterly earnings data on Monday, November, 14th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by $0.01. The business had revenue of $83.23 million for the quarter, compared to the consensus estimate of $76.60 million. Sema4 had a negative net margin of 121.31% and a negative trailing twelve-month return on equity of 53.31%. What guidance has Sema4 issued on next quarter's earnings? Sema4 updated its FY 2023 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $205.00 million-$220.00 million, compared to the consensus revenue estimate of $217.84 million. What is Sema4's stock symbol? Sema4 trades on the NASDAQ under the ticker symbol "SMFR." Who are Sema4's major shareholders? Sema4's stock is owned by many different retail and institutional investors. Top institutional investors include Trellus Management Company LLC (0.29%). Insiders that own company stock include Anthony Prentice, Daniel Emmett Clark, Eric Schadt, Isaac Ro, James Coffin, Jason Ryan, Kareem Saad, Karen Ann White, Katherine Stueland, Keith A Meister, Kevin Feeley, Richard Miao, Shawn Assad and Tactical Opportunit Blackstone. View institutional ownership trends. How do I buy shares of Sema4? Shares of SMFR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Sema4's stock price today? One share of SMFR stock can currently be purchased for approximately $0.42. How much money does Sema4 make? Sema4 (NASDAQ:SMFR) has a market capitalization of $160.26 million and generates $212.20 million in revenue each year. The company earns $-245,390,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. How many employees does Sema4 have? The company employs 1,200 workers across the globe. How can I contact Sema4? Sema4's mailing address is 667 Madison Avenue, New York NY, 10065. The official website for the company is cmlifesciencesspac.com. The company can be reached via phone at 800-298-6470 or via email at investors@sema4.com. This page (NASDAQ:SMFR) was last updated on 2/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.